Try a new search

Format these results:

Searched for:

person:nowaka01

in-biosketch:true

Total Results:

148


Annals editors on the war in Ukraine [Editorial]

Grayson, Mitchell H; Borish, Larry; Castells, Mariana C; Greenhawt, Matthew J; Leung, Donald Y M; Lieberman, Jay A; Marshall, Gailen D; Nowak-Wegrzyn, Anna; Oppenheimer, John; Shaker, Marcus S; Shulenberger, Kurt; Spergel, Jonathan; Stukus, David R
PMID: 35342018
ISSN: 1534-4436
CID: 5200862

Updated threshold dose-distribution data for sesame [Letter]

Turner, Paul J; Gretzinger, Magdalena; Patel, Nandinee; Brough, Helen; Chinthrajah, R Sharon; Ebisawa, Motohiro; Elizur, Arnon; Koplin, Jennifer J; Peters, Rachel L; Purington, Natasha; Nowak-Wegrzyn, Anna; Saf, Sarah; Sampson, Hugh A; Westerhout, Joost; Blom, W Marty; Baumert, Joseph L; Houben, Geert F; Remington, Benjamin C
PMID: 35531634
ISSN: 1398-9995
CID: 5214082

Association of Human Milk Antibody Induction, Persistence, and Neutralizing Capacity With SARS-CoV-2 Infection vs mRNA Vaccination

Young, Bridget E; Seppo, Antti E; Diaz, Nichole; Rosen-Carole, Casey; Nowak-Wegrzyn, Anna; Cruz Vasquez, Joseline M; Ferri-Huerta, Rita; Nguyen-Contant, Phuong; Fitzgerald, Theresa; Sangster, Mark Y; Topham, David J; Järvinen, Kirsi M
Importance/UNASSIGNED:Long-term effect of parental COVID-19 infection vs vaccination on human milk antibody composition and functional activity remains unclear. Objective/UNASSIGNED:To compare temporal IgA and IgG response in human milk and microneutralization activity against SARS-CoV-2 between lactating parents with infection and vaccinated lactating parents out to 90 days after infection or vaccination. Design, Setting, and Participants/UNASSIGNED:Convenience sampling observational cohort (recruited July to December 2020) of lactating parents with infection with human milk samples collected at days 0 (within 14 days of diagnosis), 3, 7, 10, 28, and 90. The observational cohort included vaccinated lactating parents with human milk collected prevaccination, 18 days after the first dose, and 18 and 90 days after the second dose. Exposures/UNASSIGNED:COVID-19 infection diagnosed by polymerase chain reaction within 14 days of consent or receipt of messenger RNA (mRNA) COVID-19 vaccine (BNT162b2 or mRNA-1273). Main Outcomes and Measures/UNASSIGNED:Human milk anti-SARS-CoV-2 receptor-binding domain IgA and IgG and microneutralization activity against live SARS-CoV-2 virus. Results/UNASSIGNED:Of 77 individuals, 47 (61.0%) were in the infection group (mean [SD] age, 29.9 [4.4] years), and 30 (39.0%) were in the vaccinated group (mean [SD] age, 33.0 [3.4] years; P = .002). The mean (SD) age of infants in the infection and vaccinated group were 3.1 (2.2) months and 7.5 (5.2) months, respectively (P < .001). Infection was associated with a variable human milk IgA and IgG receptor-binding domain-specific antibody response over time that was classified into different temporal patterns: upward trend and level trend (33 of 45 participants [73%]) and low/no response (12 of 45 participants [27%]). Infection was associated with a robust and quick IgA response in human milk that was stable out to 90 days after diagnosis. Vaccination was associated with a more uniform IgG-dominant response with concentrations increasing after each vaccine dose and beginning to decline by 90 days after the second dose. Vaccination was associated with increased human milk IgA after the first dose only (mean [SD] increase, 31.5 [32.6] antibody units). Human milk collected after infection and vaccination exhibited microneutralization activity. Microneutralization activity increased throughout time in the vaccine group only (median [IQR], 2.2 [0] before vaccine vs 10 [4.0] after the first dose; P = .003) but was higher in the infection group (median [IQR], 20 [67] at day 28) vs the vaccination group after the first-dose human milk samples (P = .002). Both IgA and non-IgA (IgG-containing) fractions of human milk from both participants with infection and those who were vaccinated exhibited microneutralization activity against SARS-CoV-2. Conclusions and Relevance/UNASSIGNED:In this cohort study of a convenience sample of lactating parents, the pattern of IgA and IgG antibodies in human milk differed between COVID-19 infection vs mRNA vaccination out to 90 days. While infection was associated with a highly variable IgA-dominant response and vaccination was associated with an IgG-dominant response, both were associated with having human milk that exhibited neutralization activity against live SARS-CoV-2 virus.
PMID: 34757387
ISSN: 2168-6211
CID: 5050532

Tolerance development in cow's milk-allergic infants receiving amino acid-based formula: A randomized controlled trial

Chatchatee, Pantipa; Nowak-Wegrzyn, Anna; Lange, Lars; Benjaponpitak, Suwat; Chong, Kok Wee; Sangsupawanich, Pasuree; van Ampting, Marleen T J; Oude Nijhuis, Manon M; Harthoorn, Lucien F; Langford, Jane E; Knol, Jan; Knipping, Karen; Garssen, Johan; Trendelenburg, Valerie; Pesek, Robert; Davis, Carla M; Muraro, Antonella; Erlewyn-Lajeunesse, Mich; Fox, Adam T; Michaelis, Louise J; Beyer, Kirsten
BACKGROUND:Tolerance development is an important clinical outcome for infants with cow's milk allergy. OBJECTIVE:This multicenter, prospective, randomized, double-blind, controlled clinical study (NTR3725) evaluated tolerance development to cow's milk (CM) and safety of an amino acid-based formula (AAF) including synbiotics (AAF-S) comprising prebiotic oligosaccharides (oligofructose, inulin) and probiotic Bifidobacterium breve M-16V in infants with confirmed IgE-mediated CM allergy. METHODS:Subjects aged ≤13 months with IgE-mediated CM allergy were randomized to receive AAF-S (n = 80) or AAF (n = 89) for 12 months. Stratification was based on CM skin prick test wheal size and study site. After 12 and 24 months, CM tolerance was evaluated by double-blind, placebo-controlled food challenge. A logistic regression model used the all-subjects randomized data set. RESULTS:At baseline, mean ± SD age was 9.36 ± 2.53 months. At 12 and 24 months, respectively, 49% and 62% of subjects were CM tolerant (AAF-S 45% and 64%; AAF 52% and 59%), and not differ significantly between groups. During the 12-month intervention, the number of subjects reporting at least 1 adverse event did not significantly differ between groups; however, fewer subjects required hospitalization due to serious adverse events categorized as infections in the AAF-S versus AAF group (9% vs 20%; P = .036). CONCLUSIONS:After 12 and 24 months, CM tolerance was not different between groups and was in line with natural outgrowth. Results suggest that during the intervention, fewer subjects receiving AAF-S required hospitalization due to infections.
PMID: 34224785
ISSN: 1097-6825
CID: 5003742

Anti-IgE Effect of Small-Molecule-Compound Arctigenin on Food Allergy in association with a Distinct Transcriptome Profile

Ming Zhuo, Cao; Liu, Changda; Srivastava, Kamal D; Lin, Adora; Lazarski, Christopher; Wang, Lu; Maskey, Anish; Song, Ying; Chen, Xiaoke; Yang, Nan; Zambrano, Linda; Bushko, Renna; Nowak-Wegrzyn, Anna; Cox, Amanda; Liu, Zhigang; Huang, Weihua; Dunkin, David; Miao, Mingsan; Li, Xiu-Min
BACKGROUND:Excessive production of IgE plays a major role in the pathology of food allergy. In an attempt to identify anti-IgE natural products, Arctium Lappa was one of the most effective herbs among approximately 300 screened medicinal herbs. However, little is known about its anti-IgE compounds. OBJECTIVE:To identify compounds from Arctium Lappa for targeted therapy on IgE production and explore their underlying mechanisms. METHODS:Liquid-liquid extraction and column chromatographic methods were used to purify the compounds. IgE inhibitory effects were determined on IgE producing human myeloma U266 cells, peanut-allergic murine model, and PBMCs from food-allergic patients. Genes involved in IgE inhibition in PBMCs were studied by RNA sequencing. RESULTS:The main compounds isolated were identified as arctiin and arctigenin. Both compounds significantly inhibited IgE production in U266 cells, with arctigenin the most potent (IC50=5.09μg/mL). Arctigenin (at a dose of 13.3 mg/kg) markedly reduced peanut-specific IgE levels, blocked hypothermia and histamine release in a peanut-allergic mouse model. Arctigenin also significantly reduced IgE production and Th2 cytokines (IL5, IL13) by PBMCs. We found 479 differentially expressed genes in PBMCs with arctigenin treatment (p<0.001 and fold-change ≥1.5), involving 24 gene ontology terms (p<0.001, FDR <0.05); cell division was the most significant. Eleven genes including UBE2C and BCL6 were validated by qPCR. CONCLUSION/CONCLUSIONS:Arctigenin markedly inhibited IgE production in U266 cells, peanut allergic murine model and PBMCs from allergic patients by down-regulating cell division, cell cycle-related genes and up-regulating anti-inflammatory factors.
PMID: 34757674
ISSN: 1365-2222
CID: 5050552

Allergic Reactions During Travel Among Individuals With IgE-mediated Food Allergy [Meeting Abstract]

Martinez-Flores, B; Trogen, B; Nowak-Wegrzyn, A; Vasquez, J C
Rationale: Although IgE-mediated food allergies affect 7.6% of children and 9% of adults in the United States, there is limited information on the prevalence and characteristics of allergic reactions to food during travel. Understanding the reactions that occur during travel will provide at-risk passengers and carriers with the necessary information to create measures to prevent and manage these emergencies.
Method(s): We analyzed two patient registry surveys on allergic history and allergic reactions established by Food Allergy Research and Education (FARE) using SPSS.
Result(s): Out of 4956 survey respondents who described the location of their allergic reactions to foods, 86 (1.7%) reported reactions during travel. Of these, 18.6% (n=16) occurred on an airplane/in-flight, and 81.4% (n=70) were reported while commuting/in-transit. Overall, the most common sites of reported reactions were home (17.2%, n=2270) and dining out (7.4%, n=976). There were no statistically significant differences between those reporting travel-related reactions and non-travel-related reactions with regards to concomitant asthma, eczema, allergic rhinitis, drug allergy, or eosinophilic esophagitis. There was no difference in self-reported severity of the reaction and epinephrine use during the reaction. However, those reporting travel-related reactions were significantly more likely to report a lifetime history of anaphylaxis (p=0.04). Peanut and tree nuts were the most commonly identified food allergen for both travel-related reactions and non-travel-related reactions.
Conclusion(s): Allergic reactions during travel were rare in these surveys and were reported more frequently during commuting than on airplanes/in-flight. Individuals reporting travel reactions were more likely to report a lifetime history of anaphylaxis.
Copyright
EMBASE:2016656103
ISSN: 1097-6825
CID: 5157382

Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study

Jones, Stacie M; Kim, Edwin H; Nadeau, Kari C; Nowak-Wegrzyn, Anna; Wood, Robert A; Sampson, Hugh A; Scurlock, Amy M; Chinthrajah, Sharon; Wang, Julie; Pesek, Robert D; Sindher, Sayantani B; Kulis, Mike; Johnson, Jacqueline; Spain, Katharine; Babineau, Denise C; Chin, Hyunsook; Laurienzo-Panza, Joy; Yan, Rachel; Larson, David; Qin, Tielin; Whitehouse, Don; Sever, Michelle L; Sanda, Srinath; Plaut, Marshall; Wheatley, Lisa M; Burks, A Wesley
BACKGROUND:For young children with peanut allergy, dietary avoidance is the current standard of care. We aimed to assess whether peanut oral immunotherapy can induce desensitisation (an increased allergic reaction threshold while on therapy) or remission (a state of non-responsiveness after discontinuation of immunotherapy) in this population. METHODS:We did a randomised, double-blind, placebo-controlled study in five US academic medical centres. Eligible participants were children aged 12 to younger than 48 months who were reactive to 500 mg or less of peanut protein during a double-blind, placebo-controlled food challenge (DBPCFC). Participants were randomly assigned by use of a computer, in a 2:1 allocation ratio, to receive peanut oral immunotherapy or placebo for 134 weeks (2000 mg peanut protein per day) followed by 26 weeks of avoidance, with participants and study staff and investigators masked to group treatment assignment. The primary outcome was desensitisation at the end of treatment (week 134), and remission after avoidance (week 160), as the key secondary outcome, were assessed by DBPCFC to 5000 mg in the intention-to-treat population. Safety and immunological parameters were assessed in the same population. This trial is registered on ClinicalTrials.gov, NCT03345160. FINDINGS/RESULTS:Between Aug 13, 2013, and Oct 1, 2015, 146 children, with a median age of 39·3 months (IQR 30·8-44·7), were randomly assigned to receive peanut oral immunotherapy (96 participants) or placebo (50 participants). At week 134, 68 (71%, 95% CI 61-80) of 96 participants who received peanut oral immunotherapy compared with one (2%, 0·05-11) of 50 who received placebo met the primary outcome of desensitisation (risk difference [RD] 69%, 95% CI 59-79; p<0·0001). The median cumulative tolerated dose during the week 134 DBPCFC was 5005 mg (IQR 3755-5005) for peanut oral immunotherapy versus 5 mg (0-105) for placebo (p<0·0001). After avoidance, 20 (21%, 95% CI 13-30) of 96 participants receiving peanut oral immunotherapy compared with one (2%, 0·05-11) of 50 receiving placebo met remission criteria (RD 19%, 95% CI 10-28; p=0·0021). The median cumulative tolerated dose during the week 160 DBPCFC was 755 mg (IQR 0-2755) for peanut oral immunotherapy and 0 mg (0-55) for placebo (p<0·0001). A significant proportion of participants receiving peanut oral immunotherapy who passed the 5000 mg DBPCFC at week 134 could no longer tolerate 5000 mg at week 160 (p<0·001). The participant receiving placebo who was desensitised at week 134 also achieved remission at week 160. Compared with placebo, peanut oral immunotherapy decreased peanut-specific and Ara h2-specific IgE, skin prick test, and basophil activation, and increased peanut-specific and Ara h2-specific IgG4 at weeks 134 and 160. By use of multivariable regression analysis of participants receiving peanut oral immunotherapy, younger age and lower baseline peanut-specific IgE was predictive of remission. Most participants (98% with peanut oral immunotherapy vs 80% with placebo) had at least one oral immunotherapy dosing reaction, predominantly mild to moderate and occurring more frequently in participants receiving peanut oral immunotherapy. 35 oral immunotherapy dosing events with moderate symptoms were treated with epinephrine in 21 participants receiving peanut oral immunotherapy. INTERPRETATION/CONCLUSIONS:In children with a peanut allergy, initiation of peanut oral immunotherapy before age 4 years was associated with an increase in both desensitisation and remission. Development of remission correlated with immunological biomarkers. The outcomes suggest a window of opportunity at a young age for intervention to induce remission of peanut allergy. FUNDING/BACKGROUND:National Institute of Allergy and Infectious Disease, Immune Tolerance Network.
PMID: 35065784
ISSN: 1474-547x
CID: 5138862

Allergen immunotherapy and/or biologicals for IgE-mediated food allergy: A systematic review and meta-analysis

de Silva, Debra; Rodríguez Del Río, Pablo; de Jong, Nicolette W; Khaleva, Ekaterina; Singh, Chris; Nowak-Wegrzyn, Anna; Muraro, Antonella; Begin, Philippe; Pajno, Giovanni; Fiocchi, Alessandro; Sanchez, Angel; Jones, Carla; Nilsson, Caroline; Bindslev-Jensen, Carsten; Wong, Gary; Sampson, Hugh; Beyer, Kirsten; Marchisotto, Mary-Jane; Fernandez Rivas, Montserrat; Meyer, Rosan; Lau, Susanne; Nurmatov, Ulugbek; Roberts, Graham
BACKGROUND:There is substantial interest in immunotherapy and biologicals in IgE-mediated food allergy. METHODS:We searched six databases for randomized controlled trials about immunotherapy alone or with biologicals (to April 2021) or biological monotherapy (to September 2021) in food allergy confirmed by oral food challenge. We pooled the data using random-effects meta-analysis. RESULTS:We included 36 trials about immunotherapy with 2126 mainly child participants. Oral immunotherapy increased tolerance whilst on therapy for peanut (RR 9.9, 95% CI 4.5.-21.4, high certainty); cow's milk (RR 5.7, 1.9-16.7, moderate certainty) and hen's egg allergy (RR 8.9, 4.4-18, moderate certainty). The number needed to treat to increase tolerance to a single dose of 300 mg or 1000 mg peanut protein was 2. Oral immunotherapy did not increase adverse reactions (RR 1.1, 1.0-1.2, low certainty) or severe reactions in peanut allergy (RR 1,6, 0.7-3.5, low certainty), but may increase (mild) adverse reactions in cow's milk (RR 3.9, 2.1-7.5, low certainty) and hen's egg allergy (RR 7.0, 2.4-19.8, moderate certainty). Epicutaneous immunotherapy increased tolerance whilst on therapy for peanut (RR 2.6, 1.8-3.8, moderate certainty). Results were unclear for other allergies and administration routes. There were too few trials of biologicals alone (3) or with immunotherapy (1) to draw conclusions. CONCLUSIONS:Oral immunotherapy improves tolerance whilst on therapy and is probably safe in peanut, cow's milk and hen's egg allergy. More research is needed about quality of life, cost and biologicals.
PMID: 35001400
ISSN: 1398-9995
CID: 5118272

Managing Food Allergy When the Patient Is Not Highly Allergic

Sicherer, Scott H; Abrams, Elissa M; Nowak-Wegrzyn, Anna; Hourihane, Jonathan O'B
Few patients with food allergy are "highly allergic," meaning they always have severe reactions and always react to very small amounts of allergen. Standard medical approaches for allergy management have focused on the safety and lifestyle modifications this group truly needs, but consequently families with food allergy are typically advised to strictly avoid any exposure to their implicated allergens. Most food-allergic subjects are actually not reactive to very low doses, and many never experience severe reactions. There are also notable conditions where a different care plan is already commonly offered: patients with pollen-related food allergy syndrome, with food-associated exercise-induced anaphylaxis, and with resolving or mild milk or egg allergy might be advised to ingest the allergens in specific circumstances with detailed instructions. Because oral immunotherapy and allergy prevention by early exposure have emphasized alternatives to strict avoidance, there is increasing interest in prospects to forego strict avoidance in those with food allergy. For patients with a high threshold of reactivity (low-dose tolerant, high-dose mildly reactive), there may be options such as allowing the ingestion of products with precautionary allergen labels, allowing dietary indiscretions with small amounts of the allergen, or even encouraging ingestion of subthreshold amounts with therapeutic intent. These practices have not been extensively studied and could be considered controversial. If these approaches are considered, shared decision making is needed in discussing them with patients and families. This review considers the potential approaches to those who are "not highly allergic": the risks, benefits, shared decision making, and research needs.
PMID: 34098164
ISSN: 2213-2201
CID: 4924532

A Survey Examining the Impact of COVID-19 on Food Protein-Induced Enterocolitis Syndrome (FPIES)

Trogen, Brit; Jin, Hope; Cianferoni, Antonella; Chehade, Mirna; Schultz, Fallon; Chavez, Amity; Warren, Christopher; Nowak-Wegrzyn, Anna H
PMID: 34740821
ISSN: 2213-2201
CID: 5038582